Frank C. Becker

NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL.

GreenField Chemical, Inc. develops branded and generic pharmaceutical products. It offers intermediate sourcing, injectable dose from sourcing, analytical support services, and consulting services. The company was founded by Frank Becker in 1997 and is headquartered in Grayslake, IL.

Regis Technologies, Inc. is a private company that offers high-quality GC derivatization reagents for gas chromatography separations. Regis Technologies is based in Morton Grove, IL and offers a range of services including solid-state chemistry, impurity services, custom API manufacturing, and more. The company provides process and analytical development of small molecule APIs for pharma companies, as well as chromatography consumables. The company partners with pharma and biotech companies to expedite small molecule drug candidates to market with CGMP manufacturing services and products. The company also provides technical and customer support, safety data sheets, certificates of analysis, and video/literature libraries. The company has a CGMP facility with a range of equipment and capabilities to manufacture lead molecules, and they offer chromatography products including chiral and achiral columns for SFC, RPLC, and specialty reagents. Quality assurance ensures the CGMP compliance of products, tracking all CGMP production from raw material receipt to final product release.

InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ.

Cadista Holdings, Inc. developed, manufactured and distributed prescription generic pharmaceutical products. The firm provided services through its subsidiary which products commonly referred to as generics are the pharmaceutical and therapeutic equivalents of brand-name drug products and are usually marketed under their established non-proprietary drug names, rather than under a brand name. The company was founded in 1988 and was headquartered in Salisbury, MD.

Jubilant Cadista Pharmaceuticals, Inc. engages in the manufacture and distribution of prescription generic pharmaceutical products. Its products include amantadine hydrochloride, donepezil, escitalopram, felodipine, and hydrochlorothiazide. The company was founded in 1921 and is headquartered in Salisbury, MD.

Part of Teva Pharmaceutical Industries Ltd., SICOR, Inc. is a company that manufactures pharmaceuticals. The company is based in San Diego, CA. The company was founded by Harry E. Gruber, Jack W. Reich, Paul K. Laikind, Robert L. Engler. SICOR was acquired by Teva Pharmaceutical Industries Ltd. on January 22, 2004 for $3,297.10 million.